Stoke Therapeutics CMO exercises 33,850 share units

Stoke Therapeutics, Inc. chief medical officer Barry Ticho reported the vesting and exercise of restricted stock units into common shares.

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. chief medical officer Barry Ticho reported the vesting and exercise of restricted stock units into common shares. On March 15, 2026, RSU awards covering 33,850 shares of common stock were settled at a price of $0.00 per share.

These RSU awards each represent the right to receive one share of common stock upon settlement and vest in annual 25% installments beginning on March 15, 2024, March 15, 2025, and March 15, 2026, subject to continued service. Following these transactions, Ticho directly holds 53,648 shares of Stoke Therapeutics common stock.

Insider Trade Summary

33,850 shares exercised/converted

Exercise 6 txns

Insider Ticho Barry

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	13,100	$0.00	$0.00
Exercise	Restricted Stock Units	10,000	$0.00	$0.00
Exercise	Restricted Stock Units	10,750	$0.00	$0.00
Exercise	Common Stock	13,100	$0.00	$0.00
Exercise	Common Stock	10,000	$0.00	$0.00
Exercise	Common Stock	10,750	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 65,350 contracts (Direct); Common Stock — 53,648 shares (Direct)

Footnotes (4)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
2. F2. The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.
3. F3. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the Issuer through each vesting date.
4. F4. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Stoke Therapeutics (STOK) report for Barry Ticho?

Stoke Therapeutics reported that chief medical officer Barry Ticho exercised restricted stock units into 33,850 shares of common stock on March 15, 2026. These were compensation-related equity awards rather than open-market purchases or sales.

How many Stoke Therapeutics (STOK) shares does Barry Ticho hold after this Form 4?

After the March 15, 2026 transactions, Barry Ticho directly holds 53,648 shares of Stoke Therapeutics common stock. This total reflects shares received upon settlement of previously granted restricted stock unit awards that vested over time.

What type of equity awards did Barry Ticho exercise at Stoke Therapeutics (STOK)?

Barry Ticho exercised restricted stock units, where each unit represents a right to receive one share of Stoke Therapeutics common stock upon settlement. The units converted into 33,850 common shares on March 15, 2026 at a stated price of $0.00 per share.

How do Barry Ticho’s restricted stock units vest at Stoke Therapeutics (STOK)?

The restricted stock unit awards vest in four equal annual installments of 25% each. The reported awards begin vesting on March 15, 2024, March 15, 2025, and March 15, 2026, conditioned on Barry Ticho’s continued service to the company through each vesting date.

Did Barry Ticho sell any Stoke Therapeutics (STOK) shares in this Form 4?

No sales were reported. The Form 4 shows only derivative exercises coded “M,” converting restricted stock units into common shares. There are no sale transactions, gifts, or tax-withholding dispositions disclosed in this insider filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 05:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ticho Barry

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		13,100	A	$0	32,898	D
Common Stock	03/15/2026		M		10,000	A	$0	42,898	D
Common Stock	03/15/2026		M		10,750	A	$0	53,648	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/15/2026		M			13,100	(2)	03/15/2027	Common Stock	13,100	$0	13,100	D
Restricted Stock Units	(1)	03/15/2026		M			10,000	(3)	03/15/2028	Common Stock	10,000	$0	20,000	D
Restricted Stock Units	(1)	03/15/2026		M			10,750	(4)	03/15/2029	Common Stock	10,750	$0	32,250	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.

2. The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.

3. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the Issuer through each vesting date.

4. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.